DNA repair in lymphocytes from patients with secondary leukemia as measured by strand rejoining and unscheduled DNA synthesis.
The ability to repair damage to DNA was compared in 2 groups of patients having undergone treatment for leukemia, one of which developed secondary leukemia (SL), and the other without signs of secondary malignancy (treated controls). Both were related to normal controls. DNA repair was assessed in isolated peripheral lymphocytes from the patients by measuring the rejoining of strand breaks following alkylation damage to the lymphocytes or by measuring unscheduled DNA synthesis. Day-to-day variability in the assays was considerable, but findings were that 5 out of 7 SL patients had repair deficiencies as measured by their ability to rejoin strand breaks, and 5 out of 7 had increased unscheduled DNA synthesis compared to treated and normal controls. All patients with SL and 4 out of 8 treated controls had inherent strand breaks in their DNA as compared to the normal controls when measured by alkaline elution.
D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004260:DNA Repair; D004273:DNA, Neoplasm / Q000378:metabolism; D005260:Female; D006801:Humans; D007938:Leukemia / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics*; D008214:Lymphocytes / Q000187:drug effects / Q000648:ultrastructure; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D009378:Neoplasms, Multiple Primary / Q000235:genetics*; D014983:Xeroderma Pigmentosum / Q000235:genetics
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm